首页 > 最新文献

Scandinavian Journal of Surgery最新文献

英文 中文
Clinical characteristics and outcomes of patients operated for primary hyperparathyroidism at Tampere University Hospital in 2017-2018. 2017-2018年坦佩雷大学医院原发性甲状旁腺功能亢进症手术患者的临床特征和疗效。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2024-09-01 Epub Date: 2024-03-04 DOI: 10.1177/14574969241228409
Jussi Tamski, Tommi Hakala, Heini Huhtala, Saara Metso

Background and objective: Studies on the outcomes of parathyroid surgery are scarce. The aim was to report the outcomes and to study the association between pre- and peri-operative information with the outcomes of patients operated for primary hyperparathyroidism.

Methods: This was a retrospective, descriptive study with unselected patients treated surgically for primary hyperparathyroidism from a catchment population of 704,500 in Finland. Data were acquired from the electronic hospital registers based on parathyroid surgery procedure codes between 1 January 2017 and 31 December 2018. Preoperative data, surgical data, preoperative and postoperative laboratory values, histopathological findings, and postoperative clinical data were recorded.

Results: During the 2-year study period, 149 patients with primary hyperparathyroidism were treated surgically with a 97% remission rate. Surgical complications included postoperative bleeding in two patients (1%) and vocal cord paralysis in one patient (0.6%). No postoperative infections were reported. Three patients (2%) developed postoperative hypoparathyroidism necessitating the use of alfacalcidol more than 1 month after surgery. Ionized calcium measured 0-1 days after surgery was not statistically significantly associated with remission or postoperative hypoparathyroidism. Serum parathyroid hormone (PTH) assessed 0-1 days postoperatively was associated with persistent disease, but not with postoperative hypoparathyroidism. The histopathological diagnosis was adenoma or hyperplasia in 112 patients (75%), atypical adenoma in 28 patients (19%), and carcinoma in five patients (3%). Patients with parathyroid carcinoma had higher preoperative ionized calcium and PTH values than those with adenoma or hyperplasia.

Conclusions: Most patients who were operated due to primary hyperparathyroidism achieved normocalcemia after surgery, and the frequency of complications was low. Ionized calcium taken 0-1 days after surgery was not associated with remission of hyperparathyroidism or postoperative hypoparathyroidism. High postoperative serum PTH predicted persistent disease.

背景和目的:有关甲状旁腺手术效果的研究很少。本研究旨在报告原发性甲状旁腺功能亢进症患者的疗效,并研究术前和围手术期信息与疗效之间的关联:这是一项回顾性、描述性研究,研究对象是芬兰70.45万名接受过手术治疗的原发性甲状旁腺功能亢进症患者。数据来自2017年1月1日至2018年12月31日期间基于甲状旁腺手术程序代码的医院电子登记册。记录了术前数据、手术数据、术前和术后实验室值、组织病理学结果以及术后临床数据:在2年的研究期间,149名原发性甲状旁腺功能亢进症患者接受了手术治疗,缓解率为97%。手术并发症包括两名患者(1%)的术后出血和一名患者(0.6%)的声带麻痹。没有术后感染的报告。三名患者(2%)术后出现甲状旁腺功能减退,需要在术后一个多月使用阿法骨化醇。术后0-1天测量的电离钙与病情缓解或术后甲状旁腺功能减退无明显统计学关系。术后0-1天测定的血清甲状旁腺激素(PTH)与疾病持续存在有关,但与术后甲状旁腺功能减退无关。112名患者(75%)的组织病理学诊断结果为腺瘤或增生,28名患者(19%)的组织病理学诊断结果为非典型腺瘤,5名患者(3%)的组织病理学诊断结果为癌。与腺瘤或增生症患者相比,甲状旁腺癌患者的术前电离钙和PTH值更高:结论:大多数因原发性甲状旁腺功能亢进而接受手术的患者术后都能达到正常钙血症水平,且并发症发生率较低。术后0-1天服用离子钙与甲状旁腺功能亢进缓解或术后甲状旁腺功能减退无关。术后血清PTH过高预示着疾病将持续存在。
{"title":"Clinical characteristics and outcomes of patients operated for primary hyperparathyroidism at Tampere University Hospital in 2017-2018.","authors":"Jussi Tamski, Tommi Hakala, Heini Huhtala, Saara Metso","doi":"10.1177/14574969241228409","DOIUrl":"10.1177/14574969241228409","url":null,"abstract":"<p><strong>Background and objective: </strong>Studies on the outcomes of parathyroid surgery are scarce. The aim was to report the outcomes and to study the association between pre- and peri-operative information with the outcomes of patients operated for primary hyperparathyroidism.</p><p><strong>Methods: </strong>This was a retrospective, descriptive study with unselected patients treated surgically for primary hyperparathyroidism from a catchment population of 704,500 in Finland. Data were acquired from the electronic hospital registers based on parathyroid surgery procedure codes between 1 January 2017 and 31 December 2018. Preoperative data, surgical data, preoperative and postoperative laboratory values, histopathological findings, and postoperative clinical data were recorded.</p><p><strong>Results: </strong>During the 2-year study period, 149 patients with primary hyperparathyroidism were treated surgically with a 97% remission rate. Surgical complications included postoperative bleeding in two patients (1%) and vocal cord paralysis in one patient (0.6%). No postoperative infections were reported. Three patients (2%) developed postoperative hypoparathyroidism necessitating the use of alfacalcidol more than 1 month after surgery. Ionized calcium measured 0-1 days after surgery was not statistically significantly associated with remission or postoperative hypoparathyroidism. Serum parathyroid hormone (PTH) assessed 0-1 days postoperatively was associated with persistent disease, but not with postoperative hypoparathyroidism. The histopathological diagnosis was adenoma or hyperplasia in 112 patients (75%), atypical adenoma in 28 patients (19%), and carcinoma in five patients (3%). Patients with parathyroid carcinoma had higher preoperative ionized calcium and PTH values than those with adenoma or hyperplasia.</p><p><strong>Conclusions: </strong>Most patients who were operated due to primary hyperparathyroidism achieved normocalcemia after surgery, and the frequency of complications was low. Ionized calcium taken 0-1 days after surgery was not associated with remission of hyperparathyroidism or postoperative hypoparathyroidism. High postoperative serum PTH predicted persistent disease.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"254-260"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective cohort study on renal morbidity related to stoma type in inflammatory bowel disease patients following colectomy and ileal pouch-anal anastomosis surgery. 一项关于结肠切除术和回肠袋-肛门吻合术后炎症性肠病患者与造口类型相关的肾脏发病率的回顾性队列研究。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2024-09-01 Epub Date: 2024-02-27 DOI: 10.1177/14574969241228411
Simon Lundström, Pamela Buchwald, Erik Agger

Background and objective: Defunctioning loop ileostomy (DLI) is frequently used to decrease the consequences of anastomotic leak after ileal pouch-anal anastomosis (IPAA) surgery but is controversial because of stoma-associated morbidity. The aim of this study was to describe stoma-associated morbidity in IPAA-DLI patients compared with terminal ileostomy patients.

Methods: Patients treated with colectomy for inflammatory bowel disease at Skåne University Hospital, Sweden, between 2005 and 2021 were eligible for inclusion. Terminal stoma-related morbidity was measured until 12 months after colectomy, IPAA surgery, or conversion to ileorectal anastomosis, whichever occurred first. DLI-related morbidity was measured until 12 months after IPAA surgery or stoma closure, whichever occurred first. Laboratory data were reviewed up to 18 months after surgery since patients without complications were rarely subjected to blood sampling. Data on patient characteristics, renal function, surgical complications, and readmissions were collected retrospectively. Primary outcomes were DLI- and terminal ileostomy-related renal morbidity, whereas secondary outcomes focused on stoma-related complications.

Results: The study cohort consisted of 165 patients with terminal ileostomy after colectomy (median (interquartile range (IQR)): stoma time 30 (15-74) months) and 42 patients with IPAA-DLI (median (IQR): stoma time 4 (3-5) months). One case of anastomotic IPAA leakage was observed. IPAA-DLI patients more often required hospital care due to high-volume stoma output immediately after surgery (0-30 days, 29%) compared with terminal ileostomy patients (4%, p < 0.001). There were no significant differences in acute renal injury (p = 0.073) or chronic renal failure (p = 0.936) incidences between the groups. DLI closure was achieved in 95% of IPAA-DLI patients, with 5% suffering Clavien-Dindo complications > 2.

Conclusions: IPAA-DLI patients exhibited higher incidence of short-term high-volume stoma output without higher rates of acute renal injury or chronic renal failure compared with terminal ileostomy patients in this small single-center retrospective study suggesting that the risk of renal morbidity in IPAA-DLI patients may have been overestimated.

背景和目的:为了减少回肠袋-肛门吻合术(IPAA)术后吻合口漏的后果,经常使用功能失调环状回肠造口术(DLI),但由于造口相关的发病率而备受争议。本研究旨在描述 IPAA-DLI 患者与末端回肠造口术患者相比的造口相关发病率:方法:2005 年至 2021 年期间在瑞典斯科纳大学医院接受结肠切除术治疗的炎症性肠病患者均符合纳入研究的条件。与终末造口相关的发病率在结肠切除术、IPAA手术或转为回肠直肠吻合术(以先发生者为准)后12个月内进行测量。与DLI相关的发病率在IPAA手术或造口关闭后12个月内进行测量,以先发生者为准。由于无并发症的患者很少进行血液采样,因此对术后18个月内的实验室数据进行了复查。对患者特征、肾功能、手术并发症和再入院情况的数据进行了回顾性收集。主要结果是与DLI和末端回肠造口术相关的肾脏发病率,次要结果主要是与造口相关的并发症:研究队列包括165名结肠切除术后行末端回肠造口术的患者(中位数(四分位距):造口时间30(15-74)个月)和42名IPAA-DLI患者(中位数(四分位距):造口时间4(3-5)个月)。观察到一例 IPAA 吻合口漏。与末端回肠造口术患者(4%,P = 0.073)或慢性肾功能衰竭(P = 0.936)的发生率相比,IPAA-DLI 患者在术后立即(0-30 天,29%)因大量造口排出而需要住院治疗。95%的IPAA-DLI患者实现了DLI闭合,5%的患者出现Clavien-Dindo并发症>2:在这项小型单中心回顾性研究中,与末端回肠造口术患者相比,IPAA-DLI 患者的短期大容量造口输出发生率更高,但急性肾损伤或慢性肾衰竭的发生率却不高,这表明 IPAA-DLI 患者的肾脏发病风险可能被高估了。
{"title":"A retrospective cohort study on renal morbidity related to stoma type in inflammatory bowel disease patients following colectomy and ileal pouch-anal anastomosis surgery.","authors":"Simon Lundström, Pamela Buchwald, Erik Agger","doi":"10.1177/14574969241228411","DOIUrl":"10.1177/14574969241228411","url":null,"abstract":"<p><strong>Background and objective: </strong>Defunctioning loop ileostomy (DLI) is frequently used to decrease the consequences of anastomotic leak after ileal pouch-anal anastomosis (IPAA) surgery but is controversial because of stoma-associated morbidity. The aim of this study was to describe stoma-associated morbidity in IPAA-DLI patients compared with terminal ileostomy patients.</p><p><strong>Methods: </strong>Patients treated with colectomy for inflammatory bowel disease at Skåne University Hospital, Sweden, between 2005 and 2021 were eligible for inclusion. Terminal stoma-related morbidity was measured until 12 months after colectomy, IPAA surgery, or conversion to ileorectal anastomosis, whichever occurred first. DLI-related morbidity was measured until 12 months after IPAA surgery or stoma closure, whichever occurred first. Laboratory data were reviewed up to 18 months after surgery since patients without complications were rarely subjected to blood sampling. Data on patient characteristics, renal function, surgical complications, and readmissions were collected retrospectively. Primary outcomes were DLI- and terminal ileostomy-related renal morbidity, whereas secondary outcomes focused on stoma-related complications.</p><p><strong>Results: </strong>The study cohort consisted of 165 patients with terminal ileostomy after colectomy (median (interquartile range (IQR)): stoma time 30 (15-74) months) and 42 patients with IPAA-DLI (median (IQR): stoma time 4 (3-5) months). One case of anastomotic IPAA leakage was observed. IPAA-DLI patients more often required hospital care due to high-volume stoma output immediately after surgery (0-30 days, 29%) compared with terminal ileostomy patients (4%, <i>p</i> < 0.001). There were no significant differences in acute renal injury (<i>p</i> = 0.073) or chronic renal failure (<i>p</i> = 0.936) incidences between the groups. DLI closure was achieved in 95% of IPAA-DLI patients, with 5% suffering Clavien-Dindo complications > 2.</p><p><strong>Conclusions: </strong>IPAA-DLI patients exhibited higher incidence of short-term high-volume stoma output without higher rates of acute renal injury or chronic renal failure compared with terminal ileostomy patients in this small single-center retrospective study suggesting that the risk of renal morbidity in IPAA-DLI patients may have been overestimated.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"202-210"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term results of the tuberous breast: What to expect after the primary correction process? 结节性乳房的长期效果:初次矫正过程后的预期效果如何?
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2024-09-01 Epub Date: 2024-05-14 DOI: 10.1177/14574969241250213
Elena S Surcel, Päivi A Merkkola-von Schantz, Hanna Öhman, Susanna C Kauhanen

Background and aims: Tuberous breast is a rare anomaly affecting the development of mainly the female breast. It presents with varying degrees of hypoplasia in the breast base and skin. In some cases, herniation and widening of the areola is observed. The condition constitutes a great challenge for the reconstructive surgeon. In this study, the surgical cascades of implant and lipofilling corrections were compared with a focus on the need for re-interventions.

Methods: In total, 129 patients whose treatment regimen started between January 2010 and October 2020 were included in this study. Patients were categorized into two groups based on the volume correction method used (lipofilling versus implant).

Results: In 35 (27%) patients (41 breasts), breast volume increasement was executed with an implant, while 94 (73%) patients (169 breasts) underwent volume increasement with lipofilling. The mean number of operations during the primary correction process was 1.2 (range 1-5) for the implant group and 2.4 (range 1-5) for the lipofilling group. When assessing the need for re-operations within 5 years after completing the primary correction, 46% of patients in the implant group needed further surgeries, while the corresponding proportion for the lipofilling group was 21% (p = 0.04). There were six major complications, all of them in the implant group.

Conclusion: Implant-based reconstruction is associated with more revision surgeries and major complications compared to autologous lipofilling corrections. Lipofilling offers a more durable result with less re-operations over time despite initial sequential primary surgeries.

背景和目的:结节性乳房是一种罕见的畸形,主要影响女性乳房的发育。它表现为乳房基底和皮肤不同程度的发育不良。在某些病例中,还可观察到乳晕疝出和增宽。这种情况对整形外科医生来说是一个巨大的挑战。在这项研究中,我们比较了假体植入和脂肪填充矫正的手术级联,重点关注再次干预的必要性:本研究共纳入了 129 名在 2010 年 1 月至 2020 年 10 月期间开始接受治疗的患者。根据所使用的容积矫正方法(脂肪填充与植入)将患者分为两组:35例(27%)患者(41个乳房)通过植入假体增加乳房体积,94例(73%)患者(169个乳房)通过脂肪填充增加乳房体积。在初次矫正过程中,假体植入组的平均手术次数为 1.2 次(1-5 次不等),脂肪填充组为 2.4 次(1-5 次不等)。在评估完成初次矫正后 5 年内是否需要再次手术时,植入组有 46% 的患者需要再次手术,而脂肪填充组的相应比例为 21%(P = 0.04)。共出现六种主要并发症,全部发生在植入组:结论:与自体脂肪填充矫正术相比,植入物重建与更多的翻修手术和重大并发症相关。自体脂肪填充术的效果更持久,随着时间的推移再次手术的次数也会减少,尽管初次手术是连续进行的。
{"title":"Long-term results of the tuberous breast: What to expect after the primary correction process?","authors":"Elena S Surcel, Päivi A Merkkola-von Schantz, Hanna Öhman, Susanna C Kauhanen","doi":"10.1177/14574969241250213","DOIUrl":"10.1177/14574969241250213","url":null,"abstract":"<p><strong>Background and aims: </strong>Tuberous breast is a rare anomaly affecting the development of mainly the female breast. It presents with varying degrees of hypoplasia in the breast base and skin. In some cases, herniation and widening of the areola is observed. The condition constitutes a great challenge for the reconstructive surgeon. In this study, the surgical cascades of implant and lipofilling corrections were compared with a focus on the need for re-interventions.</p><p><strong>Methods: </strong>In total, 129 patients whose treatment regimen started between January 2010 and October 2020 were included in this study. Patients were categorized into two groups based on the volume correction method used (lipofilling versus implant).</p><p><strong>Results: </strong>In 35 (27%) patients (41 breasts), breast volume increasement was executed with an implant, while 94 (73%) patients (169 breasts) underwent volume increasement with lipofilling. The mean number of operations during the primary correction process was 1.2 (range 1-5) for the implant group and 2.4 (range 1-5) for the lipofilling group. When assessing the need for re-operations within 5 years after completing the primary correction, 46% of patients in the implant group needed further surgeries, while the corresponding proportion for the lipofilling group was 21% (p = 0.04). There were six major complications, all of them in the implant group.</p><p><strong>Conclusion: </strong>Implant-based reconstruction is associated with more revision surgeries and major complications compared to autologous lipofilling corrections. Lipofilling offers a more durable result with less re-operations over time despite initial sequential primary surgeries.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"246-253"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort. 肝硬化与非肝硬化肝细胞癌:全国队列中的治疗和生存差异。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2023-12-25 DOI: 10.1177/14574969231220179
Jennie Engstrand, Per Stål, Stefan Gilg, Anders Jansson, Cecilia Strömberg

Background and aims: Numerous studies have reported superior outcome for patients with hepatocellular carcinoma (HCC) in non-cirrhotic compared to cirrhotic livers. This cohort study aims to describe the clinical presentation, disease course, treatment approaches, and survival differences in a population-based setting.

Methods: Data on patients diagnosed with HCC in Sweden between 2008 and 2018 were identified and extracted from the Swedish Liver registry (SweLiv). Descriptive and survival statistics were applied.

Results: Among the 4259 identified patients, 34% had HCC in a non-cirrhotic liver. Cirrhotic patients presented at a younger age (median = 64 vs 74 years, p < 0.001) and with a poorer performance status (Eastern Cooperative Oncology Group (ECOG) = 0-1: 64% vs 69%, p = 0.024). Underlying liver disease was more prevalent among cirrhotic patients (81% vs 19%, p < 0.001). Tumors in non-cirrhotic livers were diagnosed at a more advanced stage (T3-T4: 46% vs 31%) and more frequently with metastatic disease at diagnosis (22% vs 10%, p < 0.001). Tumors were significantly larger in non-cirrhotic livers (median size of largest tumor 7.5 cm) compared to cirrhotic livers (3.5 cm) (p < 0.001). Curative interventions were more commonly intended (45% vs 37%, p < 0.001) and performed (40% vs 31%, p < 0.001) in the cirrhotic vs non-cirrhotic patients. Median survival was 19 months (95% confidence interval (CI) = 18-21 months), in patients with cirrhosis as compared to 13 months in non-cirrhotic patients (95% CI = 11-15) (p < 0.001). In the multivariable Cox regression model, cirrhosis was not an independent predictor of survival, neither among curatively nor palliatively treated patients.

Conclusion: These population-based data show that patients with HCC in a cirrhotic liver receive curative treatment to a greater extent and benefit from superior survival compared to those with HCC in a non-cirrhotic liver. The differences in survival are more attributable to patient and tumor characteristics rather than the cirrhotic status itself.

Clinical trial registration: not applicable. Patient confidentially: not applicable.

背景和目的:大量研究表明,非肝硬化肝细胞癌(HCC)患者的预后优于肝硬化患者。这项队列研究旨在描述基于人群的临床表现、病程、治疗方法和生存差异:从瑞典肝脏登记处(SweLiv)中识别并提取了2008年至2018年间瑞典确诊的HCC患者数据。应用了描述性统计和生存统计:在已确认的4259名患者中,34%的HCC发生在非肝硬化的肝脏中。肝硬化患者的发病年龄较小(中位数 = 64 岁对 74 岁,P 结论:这些基于人群的数据表明,肝硬化患者的发病年龄较小,而肝癌患者的发病年龄较大:这些基于人群的数据显示,与非肝硬化肝癌患者相比,肝硬化肝癌患者接受根治性治疗的程度更高,生存率也更高。生存率的差异更多归因于患者和肿瘤特征,而非肝硬化状态本身。患者保密:不适用。
{"title":"Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort.","authors":"Jennie Engstrand, Per Stål, Stefan Gilg, Anders Jansson, Cecilia Strömberg","doi":"10.1177/14574969231220179","DOIUrl":"10.1177/14574969231220179","url":null,"abstract":"<p><strong>Background and aims: </strong>Numerous studies have reported superior outcome for patients with hepatocellular carcinoma (HCC) in non-cirrhotic compared to cirrhotic livers. This cohort study aims to describe the clinical presentation, disease course, treatment approaches, and survival differences in a population-based setting.</p><p><strong>Methods: </strong>Data on patients diagnosed with HCC in Sweden between 2008 and 2018 were identified and extracted from the Swedish Liver registry (SweLiv). Descriptive and survival statistics were applied.</p><p><strong>Results: </strong>Among the 4259 identified patients, 34% had HCC in a non-cirrhotic liver. Cirrhotic patients presented at a younger age (median = 64 vs 74 years, p < 0.001) and with a poorer performance status (Eastern Cooperative Oncology Group (ECOG) = 0-1: 64% vs 69%, p = 0.024). Underlying liver disease was more prevalent among cirrhotic patients (81% vs 19%, p < 0.001). Tumors in non-cirrhotic livers were diagnosed at a more advanced stage (T3-T4: 46% vs 31%) and more frequently with metastatic disease at diagnosis (22% vs 10%, p < 0.001). Tumors were significantly larger in non-cirrhotic livers (median size of largest tumor 7.5 cm) compared to cirrhotic livers (3.5 cm) (p < 0.001). Curative interventions were more commonly intended (45% vs 37%, p < 0.001) and performed (40% vs 31%, p < 0.001) in the cirrhotic vs non-cirrhotic patients. Median survival was 19 months (95% confidence interval (CI) = 18-21 months), in patients with cirrhosis as compared to 13 months in non-cirrhotic patients (95% CI = 11-15) (p < 0.001). In the multivariable Cox regression model, cirrhosis was not an independent predictor of survival, neither among curatively nor palliatively treated patients.</p><p><strong>Conclusion: </strong>These population-based data show that patients with HCC in a cirrhotic liver receive curative treatment to a greater extent and benefit from superior survival compared to those with HCC in a non-cirrhotic liver. The differences in survival are more attributable to patient and tumor characteristics rather than the cirrhotic status itself.</p><p><strong>Clinical trial registration: </strong>not applicable. Patient confidentially: not applicable.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"120-130"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical complications requiring late surgical revisions after pancreatoduodenectomy increase postoperative morbidity and mortality. 胰十二指肠切除术后需要后期手术修正的手术并发症增加了术后发病率和死亡率。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2023-11-14 DOI: 10.1177/14574969231206132
Esther A Biesel, Simon Kuesters, Sophia Chikhladze, Dietrich A Ruess, Julian Hipp, Ulrich T Hopt, Stefan Fichtner-Feigl, Uwe A Wittel

Background: Pancreatoduodenectomies are complex surgical procedures with considerable postoperative morbidity and mortality. Here, we describe complications and outcomes in patients requiring surgical revisions following pancreatoduodenectomy.

Methods: A total of 1048 patients undergoing a pancreatoduodenectomy at our institution between 2002 and 2019 were analyzed retrospectively. All patients with surgical revisions were included. Revisions were divided into early and late using a cut-off of 5 days after the first surgery. Statistical significance was examined by using chi-square tests and Fisher's exact tests. Survival analysis was performed using Kaplan-Meier curves and log-rank tests.

Results: A total of 150 patients with at least 1 surgical revision after pancreatoduodenectomy were included. Notably, 64 patients had a revision during the first 5 days and were classified as early revision. Compared with the 86 patients with late revisions, we found no differences concerning wound infections, delayed gastric emptying, or acute kidney failure. After late revisions, we found significantly more cases of sepsis (31.4% late versus 15.6% early, p = 0.020) and reintubation due to respiratory failure (33.7% versus 18.8%, p = 0.031). Postoperative mortality was significantly higher within the late revision group (23.2% versus 9.4%, p = 0.030).

Conclusion: Arising complications after pancreatoduodenectomy should be addressed as early as possible as patients requiring late surgical revisions frequently developed septic complications and multiorgan failure.

背景:胰十二指肠切除术是一项复杂的手术,术后发病率和死亡率相当高。在这里,我们描述了胰十二指肠切除术后需要手术修复的患者的并发症和结果。方法:回顾性分析2002年至2019年我院行胰十二指肠切除术的1048例患者。所有接受手术修复的患者均被纳入研究。以第一次手术后5天为截止时间,将修复分为早期和晚期。采用卡方检验和Fisher精确检验检验统计学显著性。生存率分析采用Kaplan-Meier曲线和log-rank检验。结果:共纳入150例胰十二指肠切除术后至少1次手术翻修的患者。值得注意的是,64例患者在前5天内进行了翻修,并被归类为早期翻修。与86例晚期翻修的患者相比,我们发现伤口感染、胃排空延迟或急性肾衰竭方面没有差异。在后期修订后,我们发现明显更多的脓毒症(31.4%晚期对15.6%早期,p = 0.020)和因呼吸衰竭而重新插管的病例(33.7%对18.8%,p = 0.031)。晚期翻修组的术后死亡率明显更高(23.2% vs 9.4%, p = 0.030)。结论:胰十二指肠切除术后出现的并发症应尽早处理,因为需要后期手术修复的患者经常出现脓毒症并发症和多器官功能衰竭。
{"title":"Surgical complications requiring late surgical revisions after pancreatoduodenectomy increase postoperative morbidity and mortality.","authors":"Esther A Biesel, Simon Kuesters, Sophia Chikhladze, Dietrich A Ruess, Julian Hipp, Ulrich T Hopt, Stefan Fichtner-Feigl, Uwe A Wittel","doi":"10.1177/14574969231206132","DOIUrl":"10.1177/14574969231206132","url":null,"abstract":"<p><strong>Background: </strong>Pancreatoduodenectomies are complex surgical procedures with considerable postoperative morbidity and mortality. Here, we describe complications and outcomes in patients requiring surgical revisions following pancreatoduodenectomy.</p><p><strong>Methods: </strong>A total of 1048 patients undergoing a pancreatoduodenectomy at our institution between 2002 and 2019 were analyzed retrospectively. All patients with surgical revisions were included. Revisions were divided into early and late using a cut-off of 5 days after the first surgery. Statistical significance was examined by using chi-square tests and Fisher's exact tests. Survival analysis was performed using Kaplan-Meier curves and log-rank tests.</p><p><strong>Results: </strong>A total of 150 patients with at least 1 surgical revision after pancreatoduodenectomy were included. Notably, 64 patients had a revision during the first 5 days and were classified as early revision. Compared with the 86 patients with late revisions, we found no differences concerning wound infections, delayed gastric emptying, or acute kidney failure. After late revisions, we found significantly more cases of sepsis (31.4% late versus 15.6% early, p = 0.020) and reintubation due to respiratory failure (33.7% versus 18.8%, p = 0.031). Postoperative mortality was significantly higher within the late revision group (23.2% versus 9.4%, p = 0.030).</p><p><strong>Conclusion: </strong>Arising complications after pancreatoduodenectomy should be addressed as early as possible as patients requiring late surgical revisions frequently developed septic complications and multiorgan failure.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"88-97"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92157087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study. 腹膜假粘液瘤细胞减灭术和HIPEC后复发:一项单中心回顾性队列研究。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2023-10-12 DOI: 10.1177/14574969231200653
Antti Yrjönen, Laura Koskenvuo, Carola Haapamäki, Anna Lepistö

Background and aims: Pseudomyxoma peritonei (PMP) is a rare disease characterized by progressive build-up of mucinous deposits inside the abdominal cavity. The aim of this study was to investigate the effect of disease recurrence on overall survival in patients with PMP after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods: One-hundred thirty-two consecutive PMP patients treated with CRS + HIPEC at Helsinki University Hospital between 2008 and 2017 were included. The impact of clinicopathological and treatment-related characteristics on recurrence and overall survival was evaluated.

Results: The median follow-up time in the study was 5.04 (range = 0.05-11.60) years. In 121 (91.7%) patients, the disease was classified as low grade and 11 (8.3%) had high-grade disease. In the low-grade group, 26 (21.5%) patients developed a recurrence during follow-up compared to 6 (54.5%) patients in the high-grade group. In the low-grade group, cumulative survival was 98.2%, 91.4%, and 91.4% at 3, 6, and 8 years, respectively. In the high-grade group, cumulative survival was 90.0% and 78.8% at 3 and 6 years, respectively. In patients with recurrent disease, the cumulative survival was 100%, 84.6%, and 84.6% at 3, 6, and 8 years in the low-grade category and 80.0% and 60.0% at 3 and 6 years in the high-grade category, respectively. In the low-grade group, a statistically significant correlation with recurrence but not with overall survival was identified with peritoneal cancer index (PCI), carcinoembryonic antigen (CEA), and the number of affected regions.

Conclusion: The recurrence of low-grade PMP does not significantly affect overall survival of patients. Disease extent may not be a prognostic indicator after curative CRS and HIPEC in low-grade PMP.

背景和目的:腹膜假性粘液瘤(PMP)是一种罕见的疾病,其特征是腹腔内粘液沉积物的逐渐积聚。本研究旨在探讨细胞减灭术(CRS)联合腹腔内热疗(HIPEC)后PMP患者疾病复发对总生存率的影响 + 2008年至2017年间赫尔辛基大学医院的HIPEC也包括在内。评估临床病理和治疗相关特征对复发和总生存率的影响。结果:研究的中位随访时间为5.04(范围 = 0.05-11.60)年。在121名(91.7%)患者中,该疾病被归类为低级别,11名(8.3%)患者患有高级别疾病。在低级别组中,26名(21.5%)患者在随访中出现复发,而高级别组为6名(54.5%)患者。在低级别组中,3、6和8岁时的累计生存率分别为98.2%、91.4%和91.4% 年。在高级别组中,3岁和6岁时的累计生存率分别为90.0%和78.8% 年。在复发性疾病患者中,3、6和8岁时的累计生存率分别为100%、84.6%和84.6% 低级别类别的年龄,3岁和6岁时分别为80.0%和60.0% 高级类别的年份。在低级别组中,腹膜癌症指数(PCI)、癌胚抗原(CEA)和受影响区域的数量与复发有统计学显著相关性,但与总生存率无统计学显著相关性。结论:低级别PMP的复发不会显著影响患者的总生存率。在治疗低级别PMP的CRS和HIPEC后,疾病程度可能不是预后指标。
{"title":"Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.","authors":"Antti Yrjönen, Laura Koskenvuo, Carola Haapamäki, Anna Lepistö","doi":"10.1177/14574969231200653","DOIUrl":"10.1177/14574969231200653","url":null,"abstract":"<p><strong>Background and aims: </strong>Pseudomyxoma peritonei (PMP) is a rare disease characterized by progressive build-up of mucinous deposits inside the abdominal cavity. The aim of this study was to investigate the effect of disease recurrence on overall survival in patients with PMP after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).</p><p><strong>Methods: </strong>One-hundred thirty-two consecutive PMP patients treated with CRS + HIPEC at Helsinki University Hospital between 2008 and 2017 were included. The impact of clinicopathological and treatment-related characteristics on recurrence and overall survival was evaluated.</p><p><strong>Results: </strong>The median follow-up time in the study was 5.04 (range = 0.05-11.60) years. In 121 (91.7%) patients, the disease was classified as low grade and 11 (8.3%) had high-grade disease. In the low-grade group, 26 (21.5%) patients developed a recurrence during follow-up compared to 6 (54.5%) patients in the high-grade group. In the low-grade group, cumulative survival was 98.2%, 91.4%, and 91.4% at 3, 6, and 8 years, respectively. In the high-grade group, cumulative survival was 90.0% and 78.8% at 3 and 6 years, respectively. In patients with recurrent disease, the cumulative survival was 100%, 84.6%, and 84.6% at 3, 6, and 8 years in the low-grade category and 80.0% and 60.0% at 3 and 6 years in the high-grade category, respectively. In the low-grade group, a statistically significant correlation with recurrence but not with overall survival was identified with peritoneal cancer index (PCI), carcinoembryonic antigen (CEA), and the number of affected regions.</p><p><strong>Conclusion: </strong>The recurrence of low-grade PMP does not significantly affect overall survival of patients. Disease extent may not be a prognostic indicator after curative CRS and HIPEC in low-grade PMP.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"140-149"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41217833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peri-firing compression in prevention of pancreatic fistula after distal pancreatectomy: A systematic review and a cohort study. 远端胰腺切除术后围射压术预防胰瘘:一项系统回顾和队列研究。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2023-11-20 DOI: 10.1177/14574969231211084
Trond Kjeseth, Sheraz Yaqub, Bjørn Edwin, Dyre Kleive, Mushegh A Sahakyan

Background/aims: Clinically relevant postoperative pancreatic fistula (CR-POPF) after distal pancreatectomy (DP) occurs in 20%-40% of patients and remains a leading cause of morbidity and increased healthcare cost in this patient group. Recently, several studies suggested decreased risk of CR-POPF with the use of peri-firing compression (PFC) technique. The aim of this report was to conduct a systematic review to get an overview of the current knowledge on the use of PFC in DP. In addition, our experience with PFC was presented.

Methods: The systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Also, 19 patients undergoing DP with the use of PFC at Oslo University Hospital were studied. The primary endpoint was incidence of CR-POPF.

Results: Seven articles reporting a total of 771 patients were ultimately included in the systematic review. Only two of these were case-control studies examining outcomes in patients with and without PFC, while the rest were case series. These were heterogeneous in terms of staplers used, cartridge selection policy, and PFC technique. Both case-control studies reported significantly reduced CR- POPF incidence with PFC. Eight (21%) of our patients developed CR-POPF after DP with PFC. Only one patient developed CR-POPF among those with pancreatic transection site thickness ⩽1.5 cm.

Conclusion: Evidence on potential benefits of PFC in DP is limited in quantity and quality. Our findings suggest that the use of PFC does not lead to reduction in the incidence of CR-POPF. Yet, there might be a benefit from PFC when dealing with a thin pancreas.

背景/目的:临床上相关的胰瘘(CR-POPF)在远端胰腺切除术(DP)后发生在20%-40%的患者中,并且仍然是该患者组发病率和医疗费用增加的主要原因。最近,一些研究表明,使用围射压(PFC)技术可以降低CR-POPF的风险。本报告的目的是进行一个系统的审查,以获得对PFC在DP中使用的当前知识的概述。此外,还介绍了我们在PFC方面的经验。方法:按照系统评价和荟萃分析首选报告项目(PRISMA)指南进行系统文献综述。此外,对奥斯陆大学医院19例使用PFC的DP患者进行了研究。主要终点为CR-POPF的发生率。结果:7篇共771例患者的文章最终被纳入系统评价。其中只有两项是病例对照研究,检查了有PFC和没有PFC的患者的结果,而其余的是病例系列研究。在使用的订书机、墨盒选择策略和PFC技术方面,这些都是异质的。两项病例对照研究均报告了pfc合并CR-POPF发生率显著降低。8例(21%)患者在pfc合并DP后发生CR-POPF。在胰腺横断部位厚度≥1.5 cm的患者中,仅有1例患者发生CR-POPF。结论:关于PFC治疗DP潜在益处的证据在数量和质量上都是有限的。我们的研究结果表明,使用PFC不会导致CR-POPF发生率的降低。然而,在处理薄胰腺时,PFC可能有一个好处。
{"title":"Peri-firing compression in prevention of pancreatic fistula after distal pancreatectomy: A systematic review and a cohort study.","authors":"Trond Kjeseth, Sheraz Yaqub, Bjørn Edwin, Dyre Kleive, Mushegh A Sahakyan","doi":"10.1177/14574969231211084","DOIUrl":"10.1177/14574969231211084","url":null,"abstract":"<p><strong>Background/aims: </strong>Clinically relevant postoperative pancreatic fistula (CR-POPF) after distal pancreatectomy (DP) occurs in 20%-40% of patients and remains a leading cause of morbidity and increased healthcare cost in this patient group. Recently, several studies suggested decreased risk of CR-POPF with the use of peri-firing compression (PFC) technique. The aim of this report was to conduct a systematic review to get an overview of the current knowledge on the use of PFC in DP. In addition, our experience with PFC was presented.</p><p><strong>Methods: </strong>The systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Also, 19 patients undergoing DP with the use of PFC at Oslo University Hospital were studied. The primary endpoint was incidence of CR-POPF.</p><p><strong>Results: </strong>Seven articles reporting a total of 771 patients were ultimately included in the systematic review. Only two of these were case-control studies examining outcomes in patients with and without PFC, while the rest were case series. These were heterogeneous in terms of staplers used, cartridge selection policy, and PFC technique. Both case-control studies reported significantly reduced CR- POPF incidence with PFC. Eight (21%) of our patients developed CR-POPF after DP with PFC. Only one patient developed CR-POPF among those with pancreatic transection site thickness ⩽1.5 cm.</p><p><strong>Conclusion: </strong>Evidence on potential benefits of PFC in DP is limited in quantity and quality. Our findings suggest that the use of PFC does not lead to reduction in the incidence of CR-POPF. Yet, there might be a benefit from PFC when dealing with a thin pancreas.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"73-79"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short- and long-term outcome after colon cancer resections performed by male and female surgeons: A single-center retrospective cohort study. 由男性和女性外科医生实施结肠癌切除术后的短期和长期疗效:单中心回顾性队列研究。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2024-02-18 DOI: 10.1177/14574969241228510
Jenny Engdahl, Astrid Öberg, Sandra Bech-Larsen, Henrik Bergenfeldt, Tomas Vedin, Marcus Edelhamre, Stefan Öberg

Background and objective: To assess the effect of surgeon sex on short- and long-term outcomes after colon cancer resections.

Methods: Clinical data of patients who underwent colon cancer resections between 2010 and 2020 at Helsingborg Hospital, Sweden, were retrospectively obtained from medical records. The sex of the surgeon of each procedure was recorded. Morbidity, mortality, and long-term survival were compared in patients operated by male and female surgeons.

Results: Colon cancer resections were performed by 23 male and 9 female surgeons in 1113 patients (79% elective, 21% emergent). After elective surgery, there was no difference in postoperative complications, 30-day mortality, or long-term survival between patients operated by male and female surgeons. Following emergent resections, the complication rate was significantly lower in patients operated by female surgeons (41.3% vs 58.1%, p = 0.019). Similarly, the rates of R1-resections (0% vs 5.2%, p = 0.039), reoperations (3.8% vs 14.2%, p = 0.014), and intensive care unit (ICU) care (6.3% vs 17.4%, p = 0.018) were significantly lower for patients operated by female surgeons, but there was no difference in 30-day mortality (6.3% vs 5.2%, p = 0.767). Cox regression analysis showed that long-term and cancer-free survival in patients emergently operated by male surgeons was significantly shorter than that of patients operated by female surgeons (hazard ratio = 1.9 (95% confidence interval (CI) = 1.3-2.8), p = 0.001 and hazard ratio = 1.7 (95% CI = 1.1-2.7), p = 0.016).

Conclusions: The short- and long-term outcome after elective colon cancer resections were similar in patients operated by male and female surgeons. The outcome following emergent resections performed by female surgeons compared favorably with that of male surgeons, with fewer complications and reoperations and better long-term survival.

背景和目的评估外科医生性别对结肠癌切除术后短期和长期预后的影响:我们从病历中回顾性地获取了瑞典赫尔辛堡医院 2010 年至 2020 年期间接受结肠癌切除术的患者的临床数据。每次手术的外科医生性别均有记录。比较了由男性和女性外科医生手术的患者的发病率、死亡率和长期生存率:结肠癌切除术由 23 名男性外科医生和 9 名女性外科医生为 1113 名患者实施(79% 为择期手术,21% 为急诊手术)。在择期手术后,由男性和女性外科医生进行手术的患者在术后并发症、30 天死亡率或长期生存率方面没有差异。急诊切除术后,女医生手术患者的并发症发生率明显降低(41.3% vs 58.1%,P = 0.019)。同样,女医生手术患者的R1切除率(0% vs 5.2%,p = 0.039)、再手术率(3.8% vs 14.2%,p = 0.014)和重症监护室(ICU)护理率(6.3% vs 17.4%,p = 0.018)也明显较低,但30天死亡率(6.3% vs 5.2%,p = 0.767)却没有差异。Cox回归分析显示,由男性外科医生紧急手术的患者的长期生存期和无癌生存期明显短于由女性外科医生手术的患者(危险比 = 1.9(95% 置信区间 (CI) = 1.3-2.8),p = 0.001;危险比 = 1.7(95% 置信区间 (CI) = 1.1-2.7),p = 0.016):由男性和女性外科医生进行择期结肠癌切除术的患者的短期和长期预后相似。由女医生进行紧急切除术后的结果优于男医生,并发症和再次手术更少,长期生存率更高。
{"title":"Short- and long-term outcome after colon cancer resections performed by male and female surgeons: A single-center retrospective cohort study.","authors":"Jenny Engdahl, Astrid Öberg, Sandra Bech-Larsen, Henrik Bergenfeldt, Tomas Vedin, Marcus Edelhamre, Stefan Öberg","doi":"10.1177/14574969241228510","DOIUrl":"10.1177/14574969241228510","url":null,"abstract":"<p><strong>Background and objective: </strong>To assess the effect of surgeon sex on short- and long-term outcomes after colon cancer resections.</p><p><strong>Methods: </strong>Clinical data of patients who underwent colon cancer resections between 2010 and 2020 at Helsingborg Hospital, Sweden, were retrospectively obtained from medical records. The sex of the surgeon of each procedure was recorded. Morbidity, mortality, and long-term survival were compared in patients operated by male and female surgeons.</p><p><strong>Results: </strong>Colon cancer resections were performed by 23 male and 9 female surgeons in 1113 patients (79% elective, 21% emergent). After elective surgery, there was no difference in postoperative complications, 30-day mortality, or long-term survival between patients operated by male and female surgeons. Following emergent resections, the complication rate was significantly lower in patients operated by female surgeons (41.3% vs 58.1%, p = 0.019). Similarly, the rates of R1-resections (0% vs 5.2%, p = 0.039), reoperations (3.8% vs 14.2%, p = 0.014), and intensive care unit (ICU) care (6.3% vs 17.4%, p = 0.018) were significantly lower for patients operated by female surgeons, but there was no difference in 30-day mortality (6.3% vs 5.2%, p = 0.767). Cox regression analysis showed that long-term and cancer-free survival in patients emergently operated by male surgeons was significantly shorter than that of patients operated by female surgeons (hazard ratio = 1.9 (95% confidence interval (CI) = 1.3-2.8), p = 0.001 and hazard ratio = 1.7 (95% CI = 1.1-2.7), p = 0.016).</p><p><strong>Conclusions: </strong>The short- and long-term outcome after elective colon cancer resections were similar in patients operated by male and female surgeons. The outcome following emergent resections performed by female surgeons compared favorably with that of male surgeons, with fewer complications and reoperations and better long-term survival.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"131-139"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computed tomography -defined sarcopenia is associated with long-term survival among patients undergoing open thoracic aortic reconstruction. 计算机断层扫描确定的肌肉疏松症与接受开胸主动脉重建术的患者的长期存活率有关。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2023-12-14 DOI: 10.1177/14574969231213758
Salla Valkkio, Sohvi Kuoppala, Iisa Lindström, Niina Khan, Thanos Sioris, Jari Laurikka, Niku Oksala, Jussi Hernesniemi

Background and objective: As markers of sarcopenia, psoas muscle areas and indexes measured from computed tomography images have been found to predict long-term mortality in cardiothoracic as well as other surgical cohorts. Our objective was to investigate the association between psoas muscle status, taking into account muscle density in addition to area, and survival among patients undergoing open thoracic aortic reconstruction.

Methods: This was a retrospective registry study of a total of 451 patients treated with open surgery for thoracic aortic pathology. Psoas muscle area and density were measured from preoperative computed tomography images at the L3 and L4 lumbar levels. In addition, lean psoas muscle area was calculated by averaging sex-specific values of psoas muscle area and density. The association between mortality and psoas muscle status was analyzed with adjusted Cox-regression analysis.

Results: The median age of the study population was 63 (interquartile range (IQR): 53-70) years. The majority were male (74.7%, n = 337) and underwent elective procedures (58.1% n = 262). Surgery of the ascending aorta was carried out in 90% of the patients, and 15% (n = 67) had concomitant coronary artery bypass surgery. Aortic dissection was present in 34.6% (n = 156) patients. Median follow-up time was 4.3 years (IQR: 2.2-7.4). During the follow-up, 106 patients (23.5%) died, with 55.7% of deaths occurring within the first four postoperative weeks. Psoas muscle parameters were not associated with perioperative mortality, but significant independent associations with long-term mortality were observed for psoas muscle area, density, and lean psoas muscle area with hazard ratios (HRs) of 0.63 (95% confidence interval (CI): 0.45-0.88), 0.62 (95% CI: 0.46-0.83), and 0.47 (95% CI: 0.32-0.69), respectively (all per 1-SD increase).

Conclusions: Psoas muscle sarcopenia status is associated with long-term mortality after open thoracic aortic surgery.

背景和目的:作为肌肉疏松症的标志,通过计算机断层扫描图像测量的腰肌面积和指数可预测心胸手术和其他手术组群的长期死亡率。我们的目的是研究腰肌状态(除面积外还考虑肌肉密度)与开胸主动脉重建患者生存之间的关系:这是一项回顾性登记研究,共对 451 名接受开胸主动脉病理手术治疗的患者进行了研究。腰肌面积和密度是通过术前腰椎 L3 和 L4 位置的计算机断层扫描图像测量的。此外,还通过计算腰肌面积和密度的性别特异性平均值来计算瘦腰肌面积。通过调整后的 Cox 回归分析,分析了死亡率与腰肌状态之间的关系:研究对象的中位年龄为 63 岁(四分位距(IQR):53-70)。大部分为男性(74.7%,n = 337),接受了选择性手术(58.1%,n = 262)。90%的患者接受了升主动脉手术,15%(n = 67)的患者同时接受了冠状动脉搭桥手术。34.6%(156 人)的患者存在主动脉夹层。中位随访时间为 4.3 年(IQR:2.2-7.4)。在随访期间,106 名患者(23.5%)死亡,其中 55.7% 的死亡发生在术后头四周内。腰肌参数与围手术期死亡率无关,但观察到腰肌面积、密度和瘦腰肌面积与长期死亡率有显著的独立关联,危险比(HRs)分别为0.63(95% 置信区间(CI):0.45-0.88)、0.62(95% CI:0.46-0.83)和0.47(95% CI:0.32-0.69)(均为每增加1SD):腰肌疏松状态与开胸主动脉手术后的长期死亡率有关。
{"title":"Computed tomography -defined sarcopenia is associated with long-term survival among patients undergoing open thoracic aortic reconstruction.","authors":"Salla Valkkio, Sohvi Kuoppala, Iisa Lindström, Niina Khan, Thanos Sioris, Jari Laurikka, Niku Oksala, Jussi Hernesniemi","doi":"10.1177/14574969231213758","DOIUrl":"10.1177/14574969231213758","url":null,"abstract":"<p><strong>Background and objective: </strong>As markers of sarcopenia, psoas muscle areas and indexes measured from computed tomography images have been found to predict long-term mortality in cardiothoracic as well as other surgical cohorts. Our objective was to investigate the association between psoas muscle status, taking into account muscle density in addition to area, and survival among patients undergoing open thoracic aortic reconstruction.</p><p><strong>Methods: </strong>This was a retrospective registry study of a total of 451 patients treated with open surgery for thoracic aortic pathology. Psoas muscle area and density were measured from preoperative computed tomography images at the L3 and L4 lumbar levels. In addition, lean psoas muscle area was calculated by averaging sex-specific values of psoas muscle area and density. The association between mortality and psoas muscle status was analyzed with adjusted Cox-regression analysis.</p><p><strong>Results: </strong>The median age of the study population was 63 (interquartile range (IQR): 53-70) years. The majority were male (74.7%, n = 337) and underwent elective procedures (58.1% n = 262). Surgery of the ascending aorta was carried out in 90% of the patients, and 15% (n = 67) had concomitant coronary artery bypass surgery. Aortic dissection was present in 34.6% (n = 156) patients. Median follow-up time was 4.3 years (IQR: 2.2-7.4). During the follow-up, 106 patients (23.5%) died, with 55.7% of deaths occurring within the first four postoperative weeks. Psoas muscle parameters were not associated with perioperative mortality, but significant independent associations with long-term mortality were observed for psoas muscle area, density, and lean psoas muscle area with hazard ratios (HRs) of 0.63 (95% confidence interval (CI): 0.45-0.88), 0.62 (95% CI: 0.46-0.83), and 0.47 (95% CI: 0.32-0.69), respectively (all per 1-SD increase).</p><p><strong>Conclusions: </strong>Psoas muscle sarcopenia status is associated with long-term mortality after open thoracic aortic surgery.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"150-159"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome after total pancreatectomy with islet autotransplantation: A European single-center study. 胰岛自体移植全胰腺切除术后的效果:欧洲单中心研究。
IF 2.5 3区 医学 Q1 SURGERY Pub Date : 2024-06-01 Epub Date: 2023-12-25 DOI: 10.1177/14574969231220176
Klara Fröberg, Asif Halimi, Miroslav Vujasinovic, José Caballero-Corbalan, Urban Arnelo, Ernesto Sparrelid, Olle Korsgren, Johannes-Matthias Löhr, Torbjörn Lundgren, Poya Ghorbani

Background and aims: Chronic pancreatitis may cause intractable abdominal pain, with total pancreatectomy sometimes being the last resort. To mitigate the subsequent diabetes, total pancreatectomy can be followed by islet autotransplantation (TP-IAT). The primary aim of this study was to assess the outcomes in patients undergoing TP-IAT at Karolinska University Hospital with respect to safety, postoperative complications, and islet graft function. A secondary aim was to compare liver to skeletal muscle as autotransplantation sites.

Methods: Single-center observational cohort study on patients undergoing TP-IAT. Islets were transplanted either into the liver or skeletal muscle. Data on baseline characteristics and pretransplantory conditions were collected. Outcome measures included mortality and major postoperative complications as well as the glycemic measures: insulin use, fasting C-peptide, and HbA1c.

Results: Between 2004 and 2020, 24 patients underwent TP-IAT. Islets were transplanted into the liver in 9 patients and into skeletal muscle in 15 patients. There was no 90-day mortality, and major complications (Clavien-Dindo ⩾IIIa) occurred in 26.7%, all related to the procedure of total pancreatectomy. Fasting C-peptide could be detected postoperatively, with higher levels in patients receiving islet autotransplantation into the liver (p = 0.006). Insulin independence was not achieved, although insulin doses at last follow-up were significantly lower in patients receiving islet autotransplantation into the liver compared to skeletal muscle (p = 0.036).

Conclusion: TP-IAT is safe and associated with tolerable risk, the component of islet autotransplantation being seemingly harmless. Although islet grafts maintain some endocrine function, insulin independence should not be expected. Regarding islet autotransplantation sites, the liver seems superior to skeletal muscle.

Clinical trial registration: Not applicable.

背景和目的:慢性胰腺炎可能会引起难治性腹痛,有时不得已会进行全胰腺切除术。为减轻后续糖尿病,全胰腺切除术后可进行胰岛自体移植(TP-IAT)。这项研究的主要目的是评估在卡罗林斯卡大学医院接受TP-IAT的患者在安全性、术后并发症和胰岛移植功能方面的疗效。次要目的是比较肝脏和骨骼肌作为自体移植部位的效果:方法:对接受 TP-IAT 的患者进行单中心观察性队列研究。方法:对接受TP-IAT的患者进行单中心观察性队列研究,将血小板移植到肝脏或骨骼肌。收集基线特征和移植前情况的数据。结果测量包括死亡率、术后主要并发症以及血糖测量:胰岛素使用、空腹血糖肽和 HbA1c:2004年至2020年间,24名患者接受了TP-IAT。9名患者的胰岛被移植到肝脏,15名患者的胰岛被移植到骨骼肌。90天内无死亡病例,主要并发症(Clavien-Dindo ⩾IIIa)发生率为26.7%,均与全胰腺切除术有关。术后可检测到空腹 C 肽,接受肝脏胰岛自体移植的患者 C 肽水平更高(p = 0.006)。虽然接受肝脏胰岛自体移植的患者最后一次随访时的胰岛素剂量明显低于骨骼肌患者(p = 0.036),但患者并未实现胰岛素独立:结论:TP-IAT 是安全的,风险可以承受,胰岛自体移植的成分似乎无害。虽然胰岛移植后仍能保持一定的内分泌功能,但不应期望胰岛素独立。关于胰岛自体移植的部位,肝脏似乎优于骨骼肌:临床试验注册:不适用。
{"title":"Outcome after total pancreatectomy with islet autotransplantation: A European single-center study.","authors":"Klara Fröberg, Asif Halimi, Miroslav Vujasinovic, José Caballero-Corbalan, Urban Arnelo, Ernesto Sparrelid, Olle Korsgren, Johannes-Matthias Löhr, Torbjörn Lundgren, Poya Ghorbani","doi":"10.1177/14574969231220176","DOIUrl":"10.1177/14574969231220176","url":null,"abstract":"<p><strong>Background and aims: </strong>Chronic pancreatitis may cause intractable abdominal pain, with total pancreatectomy sometimes being the last resort. To mitigate the subsequent diabetes, total pancreatectomy can be followed by islet autotransplantation (TP-IAT). The primary aim of this study was to assess the outcomes in patients undergoing TP-IAT at Karolinska University Hospital with respect to safety, postoperative complications, and islet graft function. A secondary aim was to compare liver to skeletal muscle as autotransplantation sites.</p><p><strong>Methods: </strong>Single-center observational cohort study on patients undergoing TP-IAT. Islets were transplanted either into the liver or skeletal muscle. Data on baseline characteristics and pretransplantory conditions were collected. Outcome measures included mortality and major postoperative complications as well as the glycemic measures: insulin use, fasting C-peptide, and HbA1c.</p><p><strong>Results: </strong>Between 2004 and 2020, 24 patients underwent TP-IAT. Islets were transplanted into the liver in 9 patients and into skeletal muscle in 15 patients. There was no 90-day mortality, and major complications (Clavien-Dindo ⩾IIIa) occurred in 26.7%, all related to the procedure of total pancreatectomy. Fasting C-peptide could be detected postoperatively, with higher levels in patients receiving islet autotransplantation into the liver (p = 0.006). Insulin independence was not achieved, although insulin doses at last follow-up were significantly lower in patients receiving islet autotransplantation into the liver compared to skeletal muscle (p = 0.036).</p><p><strong>Conclusion: </strong>TP-IAT is safe and associated with tolerable risk, the component of islet autotransplantation being seemingly harmless. Although islet grafts maintain some endocrine function, insulin independence should not be expected. Regarding islet autotransplantation sites, the liver seems superior to skeletal muscle.</p><p><strong>Clinical trial registration: </strong>Not applicable.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":" ","pages":"80-87"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Journal of Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1